Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL687517 | 0.90 | ILK (0.72) | ILK | |
| SCHEMBL686934 | 0.83 | ILK (0.70) | ILK | |
| SCHEMBL686453 | 0.81 | ILK (0.70) | ILK | |
| SCHEMBL686489 | 0.79 | ILK (0.72) | ILK | |
| SCHEMBL687608 | 0.78 | ILK (0.55) | ILK | |
| SCHEMBL686809 | 0.78 | ILK (0.72) | ILK | |
| SCHEMBL686899 | 0.78 | ILK (0.57) | ILK | |
| SCHEMBL686473 | 0.77 | ILK (0.76) | ILK | |
| SCHEMBL687029 | 0.77 | ILK (0.49) | ILK | |
| SCHEMBL687560 | 0.76 | ILK (0.76) | ILK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434720-B2 | Pyrazolylbenzothiazole derivatives and their use as therapeutic agents | DIRMIRA (CANADA), INC. (US) | 2016-09-06 | — | — | US | claimed |
| US-20140350009-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA (CANADA), INC. (US) | 2014-11-27 | — | — | US | claimed |
| EP-1542997-B1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | DERMIRA CANADA INC (CA) | 2012-02-29 | — | — | EP | claimed |
| US-7847101-B2 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | Valocor Therapeutics, Inc. (CA) | 2010-12-07 | — | — | US | claimed |
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | QLT INC. (CA) | 2006-11-02 | — | — | US | claimed |
| EP-0553887-A2 | Catalysts and epoxy resin composition containing the same | THE DOW CHEMICAL COMPANY (US) | 1993-08-04 | — | — | EP | claimed |
| US-4925901-A | STORAGE STAABILITY, ONIUM ION CATALYST | THE DOW CHEMICAL COMPANY (US) | 1990-05-15 | — | — | US | claimed |
| EP-3668936-B1 | TWO-COMPONENT ROOM TEMPERATURE CURABLE TOUGHENED EPOXY ADHESIVES | DDP SPECIALTY ELECTRONIC MATERIALS US LLC (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3844202-B1 | EPOXY COMPOSITE FORMULATION | DOW GLOBAL TECHNOLOGIES LLC (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024015165-A1 | ADHESIVE COMPOSITION | DDP SPECIALTY ELECTRONIC MATERIALS US, LLC (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024015163-A1 | ADHESIVE COMPOSITION | DDP SPECIALTY ELECTRONIC MATERIALS US, LLC (US) | 2024-01-18 | — | — | WO | disclosed |
| EP-3405510-B2 | ONE-COMPONENT EPOXY-MODIFIED POLYURETHANE AND/OR POLYUREA ADHESIVES HAVING HIGH ELONGATION AND EXCELLENT THERMAL STABILITY, AND ASSEMBLY PROCESSES USING SAME | DOW GLOBAL TECHNOLOGIES LLC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-4116385-A1 | AQUEOUS DUAL-COMPONENT WOODWARE SEALING PRIMER | Guangdong Huarun Paints Co. Ltd. (CN) | 2023-01-11 | — | — | EP | disclosed |
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | QLT INC. (CA) | 2006-11-02 | — | — | US | disclosed |
| US-6194024-B1 | CONNECTING TWO CIRCUIT CARRIERS; FILLING HOLE WITH SOLDER SPHERE | INTERNATIONAL BUSINESS MACHINES CORPORATION | 2001-02-27 | — | — | US | disclosed |
| EP-0729484-B1 | CURE INHIBITED EPOXY RESIN COMPOSITIONS AND LAMINATES PREPARED FROM THE COMPOSITIONS | DOW CHEMICAL CO (US) | 2000-03-01 | — | — | EP | disclosed |
| US-5571593-A | CIRCUIT CARRIERS | INTERNATIONAL BUSINESS MACHINES CORPORATION (US) | 1996-11-05 | — | — | US | disclosed |
| US-5503937-A | MIXTURE OF A COMPOUND HAVING MORE THAN ONE EPOXY GROUP, A DIHYDRIC PHENOLIC COMPOUND AND A LATENT CATALYST COMPRISING A SALT OF AN N-HETEROCYCLIC COMPOUND AND AN ACID HAVING A STRONG NUCLEOPHILIC ANION; COATINGS/MOLDINGS; STORAGE | THE DOW CHEMICAL COMPANY (US) | 1996-04-02 | — | — | US | disclosed |
| EP-0553887-A2 | Catalysts and epoxy resin composition containing the same | THE DOW CHEMICAL COMPANY (US) | 1993-08-04 | — | — | EP | disclosed |
| US-4925901-A | STORAGE STAABILITY, ONIUM ION CATALYST | THE DOW CHEMICAL COMPANY (US) | 1990-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247210-A1 | such as (4-Benzothiazol-2-yl-1H-pyrazol-3-yl)-[2-(1H-imidazol-4-yl)-ethyl]-amine, used in the treatment of disorders associated with hyperproliferation and tissue remodelling or repair, inflammation, cell migration and invasion, and renal diseases, or as protein kinase inhibitors | TST, PTK2, PTK2B | ILK 2153/4885HSD17B10 2968/4885 |
| US-20140350009-A1 | PYRAZOLYLBENZOTHIAZOLE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | COXFA4L2, TYR, XDH | ILK 4705/4885HSD17B10 1535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.